在癌症患者中克服阿片类药物诱导便秘管理的障碍
Esther Holgado Martín1, Ana Blasco Cordellat2, Marta Guix Arnau3
1Hospital de la Luz, Madrid, Spain.
Seminars in oncology
|November 1, 2023
概括
癌症患者的阿片类药物诱导性便秘 (OIC) 管理面临诸如患者不意识和提供者对其他症状的优先考虑等障碍. 解决方案包括有针对性的教育和简化的治疗算法.
科学领域:
- 在瘤学瘤学.
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿片类药物引起的便秘 (OIC) 是阿片类药物治疗的常见副作用.
- 有效管理OIC对于患者的生活质量和治疗坚持至关重要.
研究的目的:
- 确定实施OIC临床建议的关键障碍.
- 为改善癌症患者的OIC控制提出基于共识的解决方案.
主要方法:
- 一个科学委员会发表了关于OIC障碍和干预措施的声明.
- 一个由36名瘤学家组成的专家小组使用共识技术来评估这些陈述.
主要成果:
- 在12/45障碍和19/25干预方面达成共识.
- 确定的障碍包括患者缺乏意识,提供者症状优先级和医疗保健系统问题.
- 建议的干预措施重点是教育,改善护理协调和简化治疗算法.
结论:
- 对OIC最佳管理存在重大障碍.
- 确定了可行的策略,以克服这些障碍并加强OIC控制.
相关概念视频
Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents
214
Diarrhea, a condition marked by frequent loose or watery bowel movements, can be triggered by multiple factors such as viral or bacterial infections, food intolerances, anxiety, medications, and digestive disorders. Symptoms may include abdominal pain, bloating, nausea, and cramping. Severe or prolonged diarrhea can lead to complications like electrolyte imbalances, malnutrition, and dehydration if left untreated.
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
214
Drugs for Treatment of Constipation-Predominant IBS
181
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
181
Irritable Bowel Syndrome III: Medical and Nursing Management
214
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
214
Drugs for Treatment of Diarrhea-Predominant IBS
186
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
186
Analgesia and Pain Management
634
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
634
Opioid Analgesics: Synthetic and Semisynthetic Opioids
310
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
310


